Literature DB >> 28239647

Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG.

Raymond A Alvarez1, Ana M Maestre2, Kenneth Law1, Natasha D Durham1, Maria Ines Barria1,3, Akiko Ishii-Watabe4, Minoru Tada4, Manav Kapoor5, Mathew T Hotta1, Gabriela Rodriguez-Caprio1, Daniel S Fierer1, Ana Fernandez-Sesma2, Viviana Simon1,2,6, Benjamin K Chen1.   

Abstract

HIV-1 viremic controllers (VC) spontaneously control infection without antiretroviral treatment. Several studies indicate that IgG Abs from VCs induce enhanced responses from immune effector cells. Since signaling through Fc-γ receptors (FCGRs) modulate these Ab-driven responses, here we examine if enhanced FCGR activation is a common feature of IgG from VCs. Using an infected cell-based system, we observed that VC IgG stimulated greater FCGR2A and FCGR3A activation as compared with noncontrollers, independent of the magnitude of HIV-specific Ab binding or virus neutralization activities. Multivariate regression analysis showed that enhanced FCGR signaling was a significant predictor of VC status as compared with chronically infected patients (CIP) on highly active antiretroviral therapy (HAART). Unsupervised hierarchical clustering of patient IgG functions primarily grouped VC IgG profiles by enhanced FCGR2A, FCGR3A, or dual signaling activity. Our findings demonstrate that enhanced FCGR signaling is a common and significant predictive feature of VC IgG, with VCs displaying a distinct spectrum of FCGR activation profiles. Thus, profiling FCGR activation may provide a useful method for screening and distinguishing protective anti-HIV IgG responses in HIV-infected patients and in monitoring HIV vaccination regimens.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28239647      PMCID: PMC5313073          DOI: 10.1172/jci.insight.88226

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  64 in total

1.  NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients.

Authors:  Susanne E Johansson; Erik Rollman; Amy W Chung; Rob J Center; Bo Hejdeman; Ivan Stratov; Jorma Hinkula; Britta Wahren; Klas Kärre; Stephen J Kent; Louise Berg
Journal:  Viral Immunol       Date:  2011-09-29       Impact factor: 2.257

2.  A novel EGFP-CEM-NKr flow cytometric method for measuring antibody dependent cell mediated-cytotoxicity (ADCC) activity in HIV-1 infected individuals.

Authors:  Wannee Kantakamalakul; Kovit Pattanapanyasat; Surat Jongrakthaitae; Vatcharain Assawadarachai; Silawun Ampol; Ruengpung Sutthent
Journal:  J Immunol Methods       Date:  2006-07-17       Impact factor: 2.303

3.  Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.

Authors:  Mattia Bonsignori; Justin Pollara; M Anthony Moody; Michael D Alpert; Xi Chen; Kwan-Ki Hwang; Peter B Gilbert; Ying Huang; Thaddeus C Gurley; Daniel M Kozink; Dawn J Marshall; John F Whitesides; Chun-Yen Tsao; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Jerome H Kim; Nelson L Michael; Georgia D Tomaras; David C Montefiori; George K Lewis; Anthony DeVico; David T Evans; Guido Ferrari; Hua-Xin Liao; Barton F Haynes
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

4.  Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection.

Authors:  Anne-Sophie Dugast; Leonidas Stamatatos; Andrew Tonelli; Todd J Suscovich; Anna F Licht; Iliyana Mikell; Margaret E Ackerman; Hendrik Streeck; P J Klasse; John P Moore; Galit Alter
Journal:  Eur J Immunol       Date:  2014-08-11       Impact factor: 5.532

5.  An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum.

Authors:  Guido Ferrari; Justin Pollara; Daniel Kozink; Tiara Harms; Mark Drinker; Stephanie Freel; M Anthony Moody; S Munir Alam; Georgia D Tomaras; Christina Ochsenbauer; John C Kappes; George M Shaw; James A Hoxie; James E Robinson; Barton F Haynes
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

6.  Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding.

Authors:  Adjoa Smalls-Mantey; Nicole Doria-Rose; Rachel Klein; Andy Patamawenu; Stephen A Migueles; Sung-Youl Ko; Claire W Hallahan; Hing Wong; Bai Liu; Lijing You; Johannes Scheid; John C Kappes; Christina Ochsenbauer; Gary J Nabel; John R Mascola; Mark Connors
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

7.  Antibody-dependent effector functions against HIV decline in subjects receiving antiretroviral therapy.

Authors:  Vijaya Madhavi; Fernanda E Ana-Sosa-Batiz; Sinthujan Jegaskanda; Rob J Center; Wendy R Winnall; Matthew S Parsons; Jintanat Ananworanich; David A Cooper; Anthony D Kelleher; Denise Hsu; Sarah Pett; Ivan Stratov; Marit Kramski; Stephen J Kent
Journal:  J Infect Dis       Date:  2014-08-28       Impact factor: 5.226

8.  Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology.

Authors:  Amy W Chung; Manu P Kumar; Kelly B Arnold; Wen Han Yu; Matthew K Schoen; Laura J Dunphy; Todd J Suscovich; Nicole Frahm; Caitlyn Linde; Alison E Mahan; Michelle Hoffner; Hendrik Streeck; Margaret E Ackerman; M Juliana McElrath; Hanneke Schuitemaker; Maria G Pau; Lindsey R Baden; Jerome H Kim; Nelson L Michael; Dan H Barouch; Douglas A Lauffenburger; Galit Alter
Journal:  Cell       Date:  2015-11-05       Impact factor: 41.582

9.  Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.

Authors:  Amy W Chung; Musie Ghebremichael; Hannah Robinson; Eric Brown; Ickwon Choi; Sophie Lane; Anne-Sophie Dugast; Matthew K Schoen; Morgane Rolland; Todd J Suscovich; Alison E Mahan; Larry Liao; Hendrik Streeck; Charla Andrews; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Mark S de Souza; Jaranit Kaewkungwal; Punnee Pitisuttithum; Donald Francis; Nelson L Michael; Jerome H Kim; Chris Bailey-Kellogg; Margaret E Ackerman; Galit Alter
Journal:  Sci Transl Med       Date:  2014-03-19       Impact factor: 17.956

10.  Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.

Authors:  Nicole L Yates; Hua-Xin Liao; Youyi Fong; Allan deCamp; Nathan A Vandergrift; William T Williams; S Munir Alam; Guido Ferrari; Zhi-yong Yang; Kelly E Seaton; Phillip W Berman; Michael D Alpert; David T Evans; Robert J O'Connell; Donald Francis; Faruk Sinangil; Carter Lee; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Abraham Pinter; Susan Zolla-Pazner; Peter B Gilbert; Gary J Nabel; Nelson L Michael; Jerome H Kim; David C Montefiori; Barton F Haynes; Georgia D Tomaras
Journal:  Sci Transl Med       Date:  2014-03-19       Impact factor: 17.956

View more
  4 in total

1.  P2X1 Selective Antagonists Block HIV-1 Infection through Inhibition of Envelope Conformation-Dependent Fusion.

Authors:  Alexandra Y Soare; Hagerah S Malik; Natasha D Durham; Tracey L Freeman; Raymond Alvarez; Foramben Patel; Namita Satija; Chitra Upadhyay; Catarina E Hioe; Benjamin K Chen; Talia H Swartz
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

2.  IgG targeting distinct seasonal coronavirus- conserved SARS-CoV-2 spike subdomains correlates with differential COVID-19 disease outcomes.

Authors:  Jose L Garrido; Matías A Medina; Felipe Bravo; Sarah McGee; Francisco Fuentes-Villalobos; Mario Calvo; Yazmin Pinos; James W Bowman; Christopher D Bahl; Maria Ines Barria; Rebecca A Brachman; Raymond A Alvarez
Journal:  Cell Rep       Date:  2022-05-16       Impact factor: 9.995

Review 3.  Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV.

Authors:  Susan Zolla-Pazner; Raymond Alvarez; Xiang-Peng Kong; Svenja Weiss
Journal:  Curr Opin HIV AIDS       Date:  2019-07       Impact factor: 4.283

4.  Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice.

Authors:  Catarina E Hioe; Guangming Li; Xiaomei Liu; Ourania Tsahouridis; Xiuting He; Masaya Funaki; Jéromine Klingler; Alex F Tang; Roya Feyznezhad; Daniel W Heindel; Xiao-Hong Wang; David A Spencer; Guangnan Hu; Namita Satija; Jérémie Prévost; Andrés Finzi; Ann J Hessell; Shixia Wang; Shan Lu; Benjamin K Chen; Susan Zolla-Pazner; Chitra Upadhyay; Raymond Alvarez; Lishan Su
Journal:  PLoS Pathog       Date:  2022-01-05       Impact factor: 6.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.